BENITIONSClinical Trial Intelligence

A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age

Фаза 1/2 Завершено NCT05975099

ЗаболеваниеLyme Disease
ФазаФаза 1/2
СпонсорModernaTX, Inc.
СтатусЗавершено
Участники807 участн.
ВмешательствоmRNA-1975, mRNA-1982
Дата начала26.07.2023
Дата завершения30.05.2025
Публикация результатов30.07.2026

Кратко

The purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme disease in healthy adult participants.

Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection

Up to 7 days after Day 1 injection · Participants

mRNA-1975 Dose Level 170 Participants
mRNA-1975 Dose Level 280 Participants
mRNA-1975 Dose Level 382 Participants
mRNA-1975 Dose Level 491 Participants
mRNA-1982 Dose Level 164 Participants
mRNA-1982 Dose Level 277 Participants

Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 57 Injection

Up to 7 days after Day 57 injection · Participants

mRNA-1975 Dose Level 179 Participants
mRNA-1975 Dose Level 280 Participants
mRNA-1975 Dose Level 390 Participants
mRNA-1975 Dose Level 496 Participants
mRNA-1982 Dose Level 170 Participants
mRNA-1982 Dose Level 282 Participants

Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 169 Injection

Up to 7 days after Day 169 injection · Participants

mRNA-1975 Dose Level 181 Participants
mRNA-1975 Dose Level 287 Participants
mRNA-1975 Dose Level 381 Participants
mRNA-1975 Dose Level 492 Participants
mRNA-1982 Dose Level 176 Participants
mRNA-1982 Dose Level 282 Participants

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Все исследования

Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.